Evidence map›Paper›PMID 27185796›Full record

ArticleAntimicrobial agents and chemotherapy2016

Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Laurent Bourguignon, Yoann Cazaubon, Guillaume Debeurme, Constance Loue, Michel Ducher, Sylvain Goutelle

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Laurent BourguignonHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, Lyon, France ISPB, Faculté de Pharmacie, Université Lyon 1, Lyon, France laurent.bourguignon@chu-lyon.fr.
Yoann CazaubonHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, Lyon, France.
Guillaume DebeurmeHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France.
Constance LoueHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France.
Michel DucherHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France.
Sylvain GoutelleHospices Civils de Lyon, Groupement Hospitalier de Gériatrie, Hôpital Antoine Charial, Service Pharmaceutique, Francheville, France UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, Lyon, France ISPB, Faculté de Pharmacie, Université Lyon 1, Lyon, France.
Hospices Civils de Lyon · FRCentre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the 1950s, vancomycin has remained a reference treatment for severe infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus Vancomycin is a nephrotoxic and ototoxic drug mainly eliminated through the kidneys. It has a large interindividual pharmacokinetic variability, which justifies monitoring its plasma concentrations in patients. This is especially important in patients aged over 80 years, who frequently have renal impairment. However, the pharmacokinetics of vancomycin in this population is very poorly described in the literature. The objective of this work was to propose a model able to predict the pharmacokinetics of vancomycin in very elderly people. First, a population pharmacokinetic model was carried out using the algorithm NPAG (nonparametric adaptive grid) on a database of 70 hospitalized patients aged over 80 years and treated with vancomycin. An external validation then was performed on 41 patients, and the predictive capabilities of the model were assessed. The model had two compartments and six parameters. Body weight and creatinine clearance significantly influenced vancomycin volume of distribution and body clearance, respectively. The means (± standard deviations) of vancomycin volume of distribution and clearance were 36.3 ± 15.2 liter and 2.0 ± 0.9 liter/h, respectively. In the validation group, the bias and precision were -0.75 mg/liter and 8.76 mg/liter for population predictions and -0.39 mg/liter and 2.68 mg/liter for individual predictions. In conclusion, a pharmacokinetic model of vancomycin in a very elderly population has been created and validated for predicting plasma concentrations of vancomycin.

Indexed as

Aged, 80 and overAnti-Bacterial AgentsBody WeightFemaleHumansMaleStaphylococcus aureusVancomycinAnti-Bacterial AgentsVancomycin

Identifiers

PMID27185796
PMCPMC4958150
OpenAlexW2399390863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.